News

Adjuvant Cetuximab Fails to Boost FOLFOX in Stage III Colon Cancer

Publish date: July 2, 2012

 

AT THE WORLD CONGRESS ON GASTROINTESTINAL CANCER

Merck Serono and Sanofi-Aventis provided grants to fund the trial. Dr. Taieb has received consultancy and advisory board honoraria from Merck. Dr. Ducreux has received consultancy fees from Merck Serono and Roche.

Pages

Recommended Reading

Bevacizumab Beyond Progression Extends Survival in Metastatic CRC
MDedge Hematology and Oncology
Laparoscopy Tops Open Resection for Most Gastric Tumors
MDedge Hematology and Oncology
Screening Colonoscopy Can Benefit Selected Elderly People
MDedge Hematology and Oncology
H. Pylori Infection, Colonic Neoplasms Linked
MDedge Hematology and Oncology
Regorafenib Delays Progression of Refractory Metastatic GIST
MDedge Hematology and Oncology
Pancreatic Surgery Scorecard Aligns With IOM Quality Metrics
MDedge Hematology and Oncology
Panel Rejects New Heparin for VTE Prevention in Cancer
MDedge Hematology and Oncology
Metformin May Reduce Liver Cancer Risk
MDedge Hematology and Oncology
Vismodegib Blocks Hedgehog-Expressing Pancreatic Cancer
MDedge Hematology and Oncology
ASCO 2012: Top Gastrointestinal Cancers Studies
MDedge Hematology and Oncology